LUZHU BIOTECH-B successfully completed Phase I clinical trial of LZ901 in the United States
I'm PortAI, I can summarize articles.
LUZHU BIOTECH-B announced that its LZ901 vaccine has successfully completed Phase I clinical trials in the United States. The trial results showed that both the high-dose group and the low-dose group exhibited good safety and immunogenicity, with mild adverse reactions occurring in the low-dose group (4.35%). LZ901 is a recombinant shingles vaccine independently developed by the company, aimed at preventing shingles and related complications in adults aged 40 and above. The Phase III clinical trial of the vaccine in China has reached its preset goals, and the biologics license application is under evaluation
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments